ArticleEukaryotic cell2009
Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
Article in Eukaryotic cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Phosphoproteomics of WHO-Priority Fungal Pathogens: Conserved Signaling Architecture, Pathogen-Specific Outputs, and Therapeutic Vulnerabilities.Pathogens (Basel, Switzerland) · 2026Review
- Effects of human immunoglobulins onmBio · 2026Article
- Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV.The Journal of infectious diseases · 2025Article
- Virulence factors released by extracellular vesicles fromFrontiers in cellular and infection microbiology · 2025Review
- Article
- Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.Folia microbiologica · 2023Article
- Dangerous Liaisons: Interactions ofPathogens (Basel, Switzerland) · 2020Review
- ExploringThe Journal of biological chemistry · 2020Article
- Biology and function of exo-polysaccharides from human fungal pathogens.Current clinical microbiology reports · 2020Article
- Unraveling synthesis of the cryptococcal cell wall and capsule.Glycobiology · 2018Review
- Cryptococcal Traits Mediating Adherence to Biotic and Abiotic Surfaces.Journal of fungi (Basel, Switzerland) · 2018Review
- Cryptococcus neoformans: historical curiosity to modern pathogen.Yeast (Chichester, England) · 2014Review
- Fungal laccases and their applications in bioremediation.Enzyme research · 2014Review
- Article
- A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan.Fungal genetics and biology : FG & B · 2012Article
- Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties.Eukaryotic cell · 2012Article
- Unravelling secretion in Cryptococcus neoformans: more than one way to skin a cat.Mycopathologia · 2012Review
- Cryptococcus neoformans-derived microvesicles enhance the pathogenesis of fungal brain infection.PloS one · 2012Article
- In good company: association between fungal glycans generates molecular complexes with unique functions.Frontiers in microbiology · 2012Article
- Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans.Infection and immunity · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
Abstract
Cryptococcus neoformans capsular polysaccharide is composed of at least two components, glucuronoxylomannan (GXM) and galactoxylomannans (GalXM). Although GXM has been extensively studied, little is known about the location of GalXM in the C. neoformans capsule, in part because there are no serological reagents specific to this antigen. To circumvent the poor immunogenicity of GalXM, this antigen was conjugated to protective antigen from Bacillus anthracis as a protein carrier. The resulting conjugate elicited antibodies that reacted with GalXM in mice and yielded an immune serum that proved useful for studying GalXM in the polysaccharide capsule. In acapsular cells, immune serum localized GalXM to the cell wall. In capsulated cells, immune serum localized GalXM to discrete pockets near the capsule edge. GalXM was abundant on the nascent capsules of budding daughter cells. The constituent sugars of GalXM were found in vesicle fractions consistent with vesicular transport for this polysaccharide. In addition, we generated a single-chain fraction variable fragment antibody with specificity to oxidized carbohydrates that also produced punctate immunofluorescence on encapsulated cells that partially colocalized with GalXM. The results are interpreted to mean that GalXM is a transient component of the polysaccharide capsule of mature cells during the process of secretion. Hence, the function of GalXM appears to be more consistent with that of an exopolysaccharide than a structural component of the cryptococcal capsule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.